Back to News

Lowest Net Cost Formulary Update Bulletin - Effective July 1, 2026

June 1, 2026

The changes in this update apply only to groups that use the OptumRx Lowest Net Cost (LNC) formulary. These updates do not apply to groups using any other formulary. The majority of these updates include decisions that occurred as a result of the February 2026 Pharmacy and Therapeutics Committee (P&T) meeting. Members impacted by these changes will be sent a notification letter. 

FORMULARY UPDATES

Additions
These drugs will be added to the formulary effective July 1, 2026:

Product

 Drug Class/Category

UM Programs

Formulary Status

BrinsupriRespiratoryPA/QLNon-Preferred Specialty
DawnzeraHereditary AngioedemaPA/QLNon-Preferred Specialty
HernexeosAntineoplasticPA/QLNon-Preferred Specialty
InlexzoAntineoplasticPANon-Preferred Specialty
InluriyoAntineoplasticPA/QLNon-Preferred Specialty
JascaydRespiratoryPA/QLNon-Preferred Specialty
Leqembi IqlikAlzheimer’sPA/QLNon-Preferred Specialty
ModeysoAntineoplasticPANon-Preferred Specialty

 Exclusions

 These drugs will move to non-formulary status and be excluded from coverage effective July 1, 2026:

  •  Armour Thyroid*
  • Brilinta Tab
  • Brimonidine Gel 0.33%
  • Entresto Tab
  • Korlym Tab 300mg
  • Niva Thyroid*
  • NP Thyroid*
  • Sod Sul/Sulf Liq 10-5%
  • Sprycel Tab
  • Tasigna Cap
  • Thyroid*

 *Not eligible for formulary exception review. 

 UTILIZATION MANAGEMENT UPDATES

Quantity Limits

These drugs will have new quantity limits effective July 1, 2026:

 

Drug Name

Quantity Limit

Fanapt Tab 2 tablets/day
Fanapt Titration Pack A2 starter packs/365 days
Fanapt Titration Pack B2 starter packs/365 days
Fanapt Titration Pack C 2 starter packs/365 days
Latuda Tab1 tablet/day
Latuda Tab 80 Mg2 tablets/day
Rexulti Tab1 tablet/day
Vraylar Cap1 capsule/day
Vraylar Therapy Pack2 starter packs/365 days